Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients \>/= 18 years of age.~* Patients, who suffer from unresectable and/or metastatic, measurable predominantly clear cell RCC (renal cell carcinoma histologically) or cytologically documented.~* Patients must be previously untreated for advanced disease. Prior palliative radiation therapy is allowed if the target lesion(s) are not included within the radiation field and no more than 30% of the bone marrow is irradiated.~* Patients who have at least one uni-dimensional measurable lesion by computed tomography (CT-scan) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST).~* Patients with Intermediate or Low risk per the Motzer score.~* Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1.~* Adequate bone marrow, renal and hepatic function as assessed by the following laboratory requirements to be conducted within 7 days prior to study drug treatment~Exclusion Criteria:~* Patients who have received prior systemic treatment regimens for RCC.~* Uncontrolled/unstable cardiac disease~* Uncontrolled hypertension~* Active clinically serious infections (\> Common Terminology Criteria for Adverse Events \[CTCAE\] grade 2 )~* History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.~* Known history or symptomatic metastatic brain or meningeal tumours~* Patients with seizure disorder requiring medication~* Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event \>/= CTCAE Grade 3 within 4 weeks of first dose of study.~* Pregnant or breast-feeding patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regorafenib (Stivarga, BAY73-4506) (Type: EXPERIMENTAL): Participants received Regorafenib 160 mg per os (po) every day (qd) for 3 weeks on 1 week off of every 4 week cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).